Sall Research Medical Center   Report issue

Academic/Hospital Phase 1 Phase 3
Founded: Artesia CA United States (1986)

Organization Overview

First Clinical Trial
2013
NCT01922128
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Alternative names

Sall Eye Center

Active Ingredients

Drugs in Phase 3 Trials (1)

loteprednol (lotemax) (3 trials)

Drugs in Phase 1 Trials (2)

hydralazine (apresoline) (1 trial)

p-321 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blepharitis (Phase 2)

Dry Eye Syndromes (Phase 2)

Eye Diseases (Phase 2)

Eye Infections (Phase 3)

Inflammation (Phase 3)

Keratoconjunctivitis (Phase 2)

Keratoconjunctivitis Sicca (Phase 2)

Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3